Introduction

GLP-1 agonists, such as Ozempic, Wegovy, Rybelsus, and Saxenda, are popular medications for managing Type 2 diabetes. Recently, they have gained attention for their effectiveness in weight loss. However, new research suggests these drugs may come with significant gastrointestinal (GI) risks. A recent study examined these potential side effects in non-diabetic individuals using GLP-1 agonists for weight management.

Study Overview

Researchers from the University of British Columbia analyzed data from a large health database, including 16 million patients from 2006 to 2020. The study focused on users of semaglutide and liraglutide (two main GLP-1 agonists) and compared them to users of bupropion-naltrexone, another weight loss drug. The study included only individuals with obesity and excluded those with diabetes.

Patients were monitored from their first prescription until they experienced one of the following GI events: biliary disease, pancreatitis, bowel obstruction, or gastroparesis. The study adjusted for various factors like age, sex, lifestyle, and medical history.

The study included 4,144 liraglutide, 613 semaglutide, and 654 bupropion-naltrexone users. Findings showed higher rates of GI issues among GLP-1 agonist users:

• Biliary Disease: Higher incidence rates for semaglutide and liraglutide users compared to bupropion-naltrexone.
• Pancreatitis: GLP-1 users had significantly higher rates.
• Bowel Obstruction and Gastroparesis: Increased rates were observed in GLP-1 users.

The risks for pancreatitis, bowel obstruction, and gastroparesis were notably higher for GLP-1 users, though the risk for biliary disease was not significantly different.

This study is significant as it is the first large-scale research examining GI risks in non-diabetic patients using GLP-1 agonists for weight loss. Mohit Sodhi, a UBC medical student, highlighted the importance of considering these risks: “Although rare, these adverse events must be considered by patients thinking about using these drugs for weight loss.”

Conclusion

While GLP-1 agonists like Ozempic and Wegovy are effective for weight loss, they come with potential GI risks. Patients and healthcare providers should weigh these risks against the benefits, especially for non-diabetic individuals. As these drugs become more popular, it is crucial to ensure that patients are fully informed about the potential side effects, enabling them to make safer and more informed decisions about their weight loss strategies.

References: 

Weight-loss drugs linked to stomach paralysis, other serious gastrointestinal conditions